Oncological outcome following initiation of treatment for stage III and IV HPV negative oropharyngeal cancers with transoral robotic surgery (TORS).
19th Jun 2019
Surender Dabas,Karan Gupta
Department of Surgical Oncology, BLK Super Specialty Hospital, New Delhi, India; Department of Head-Neck Surgical Oncology, Medanta-The Medicity, Gurgaon, Haryana, India.
Former Vattikuti Fellow Dr. Karan Gupta and his Mentor Surgeon Dr. Surender Dabas have collaborated to produce an article for the European Journal of Surgical Oncology. Here is the abstract:
To report long-term oncological and functional outcome of Transoral Robotic Surgery escalated treatment including radiotherapy or chemoradiotherapy for Stage III-IV HPV negative oropharyngeal malignancies.
From March 2013 to September 2015, 153 patients with oropharyngeal carcinoma were included in the study. Patients were evaluated for disease free survival, overall survival and post-treatment functional outcomes.
153 patients (96 males and 57 females) underwent TORS for oropharyngeal carcinoma. 142 patients on final histopathology had stage III and IV disease and received adjuvant treatment based on final histopathology. One hundred and sixteen (81.7%) patients were disease free on average follow-up of 48 months with an overall survival of 91.5% at mean follow-up of 48 months.
TORS can be used to intensify treatment of Stage III/IV oropharyngeal carcinoma and avoid early and late toxicities due to higher doses of upfront RT/CTRT and achieve better oncological outcome.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Please use the journal information or PubMed link to access the complete European Journal of Surgical Oncology article:
Eur J Surg Oncol. 2019 Jun 19. pii: S0748-7983(19)30521-9. doi: 10.1016/j.ejso.2019.06.027. PMID: 31239156.